{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Alpa Laboratories Ltd
Alpa Laboratories Ltd is Rated Strong Sell
Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Alpa Laboratories Falls to 52-Week Low of Rs.73.65 Amidst Prolonged Underperformance
Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.73.65, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.
Alpa Laboratories Ltd is Rated Strong Sell
Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.
Alpa Laboratories Stock Falls to 52-Week Low of Rs.75 Amidst Continued Downtrend
Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.75, marking a significant decline in its stock price amid broader market fluctuations and sectoral underperformance.
Why is Alpa Laboratorie falling/rising?
On 05-Dec, Alpa Laboratories Ltd witnessed a notable decline in its share price, closing at ₹81.00, down ₹3.15 or 3.74% from the previous session. This drop reflects a continuation of recent weakness amid subdued investor participation and technical headwinds.
Alpa Laboratorie Sees Revision in Market Assessment Amid Challenging Financial Trends
Alpa Laboratorie, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. Recent assessment changes highlight shifts across key performance parameters, signalling caution for investors amid subdued returns and operational difficulties.
Alpa Laboratories Stock Falls to 52-Week Low of Rs.76.25
Alpa Laboratories has reached a new 52-week low, with its share price touching Rs.76.25 today. This marks a significant level for the pharmaceutical and biotechnology company amid a broader market environment where the Sensex is trading slightly lower.
Alpa Laboratories Stock Falls to 52-Week Low of Rs.78.01
Alpa Laboratories has reached a new 52-week low of Rs.78.01, marking a significant decline amid broader market gains. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.
Alpa Laboratories Falls to 52-Week Low of Rs.78.02 Amidst Market Rally
Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.78.02 today, marking a significant decline amid a broadly positive market environment where the Sensex advanced by 0.64%.
Alpa Laboratories Faces Financial Challenges Amidst Strong Sales Growth and Market Struggles
Alpa Laboratories has reported a challenging financial period for the quarter ending September 2025, with a decline in overall performance metrics. Despite a 21.86% increase in net sales to Rs 85.29 crore, profit after tax fell significantly. The company faces concerns regarding key performance indicators and market performance relative to the Sensex.
Alpa Laboratories Q2 FY26: Profit Plunges 98.57% as Operating Margins Turn Negative
Alpa Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported deeply troubling results for Q2 FY26, with consolidated net profit collapsing 98.57% year-on-year to just ₹0.11 crores from ₹7.69 crores in the same quarter last year. The catastrophic decline reflects severe operational distress as the company's operating margins turned sharply negative for the first time in recent years, raising serious questions about business viability. The stock, currently trading at ₹80.85 with a market capitalisation of ₹168.00 crores, has declined 28.70% over the past year, significantly underperforming both the benchmark Sensex and the pharmaceuticals sector.
Is Alpa Laboratorie overvalued or undervalued?
As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.
How has been the historical performance of Alpa Laboratorie?
Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 79.21
Alpa Laboratories has hit a new 52-week low of Rs. 79.21, reflecting a significant downturn after five days of gains. The stock has underperformed its sector and is trading below key moving averages. Over the past year, it has declined by 25.28%, contrasting with the Sensex's growth.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 79.21
Alpa Laboratories has hit a 52-week low of Rs. 79.21, following a five-day gain streak. The stock has underperformed its sector and is trading below all key moving averages. Despite modest growth in net sales and operating profit, its performance contrasts with broader market trends.
How has been the historical performance of Alpa Laboratorie?
Alpa Laboratorie has shown steady growth in net sales and profitability, with net sales increasing from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, and profit after tax rising from 0.93 Cr to 19.50 Cr in the same period, indicating strong financial performance and operational efficiency. Total assets also grew significantly, reflecting robust asset accumulation.
Why is Alpa Laboratorie falling/rising?
As of 07-Nov, Alpa Laboratories Ltd's stock price is Rs. 81.83, down 6.67%, hitting a 52-week low of Rs. 79.8, and underperforming its sector. The stock has declined 10.55% over the past five days and is trading below all key moving averages, indicating a bearish trend with decreased investor participation.
Alpa Laboratories Stock Plummets to New 52-Week Low at Rs. 83.3
Alpa Laboratories has reached a 52-week low, reflecting ongoing challenges in the market. The microcap pharmaceutical company has seen a consistent decline over the past week and year, underperforming compared to sector peers. Despite a stable financial structure, growth and profitability remain difficult to achieve.
Why is Alpa Laboratorie falling/rising?
As of 17-Oct, Alpa Laboratories Ltd's stock price is Rs. 85.00, down 4.49%, marking a new 52-week low and underperforming its sector. The stock has declined 6.97% over the past week and 29.17% year-to-date, significantly lagging behind the benchmark Sensex.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
